15 7月 2021 by admin in UncategorizedComments Adicet Bio Announces Formation of Scientific Advisory Board
09 7月 2021 by admin in UncategorizedComments 日本中外制药(Chugai)与礼邦医药(Alebund)就 EOS789 开发用于高磷血症治疗达成期权/授权协议
06 7月 2021 by admin in UncategorizedComments NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors
01 7月 2021 by admin in UncategorizedComments Tempest Announces Appointment of Christine Pellizzari to its Board of Directors
28 6月 2021 by admin in UncategorizedComments Tempest Closes Merger with Millendo and Completes PIPE Financing
22 6月 2021 by admin in UncategorizedComments Tempest and Millendo Announce Stockholder Approval of Merger
21 6月 2021 by admin in UncategorizedComments NextCure and Collaborators Publish Preclinical Data on Novel Immunomedicine NC410
07 6月 2021 by admin in UncategorizedComments Design Therapeutics Expands Board of Directors with Key Appointments
04 6月 2021 by admin in UncategorizedComments Arcellx Announces Presentation of Positive Clinical Results from Ongoing Phase 1 Study of CART-ddBCMA at the 2021 ASCO Annual Meeting
20 5月 2021 by admin in UncategorizedComments Crescendo Biologics announces initiation of Phase 1 study of CB307 in patients with advanced, PSMA-positive solid tumours
19 5月 2021 by admin in UncategorizedComments NextCure to Present Trials in Progress Poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
19 5月 2021 by admin in UncategorizedComments Arcellx to Present Data from Phase 1 Study of CART-ddBCMA Demonstrating Continued Positive Response in Patients with Relapsed and Refractory Multiple Myeloma at the 2021 ASCO Annual Meeting
17 5月 2021 by admin in UncategorizedComments Adicet Reports First Quarter 2021 Financial Results and Provides Business Updates
13 5月 2021 by admin in UncategorizedComments Preclinical Data of Arcellx’s Novel Synthetic CAR-T Binding Domain Presented at the 2021 ASGCT Annual Meeting and the 2021 PEGS Summit
12 5月 2021 by admin in UncategorizedComments Citrine Medicine Announces Strategic Partnership to bring Efmody® to China for Use in Adrenal Insufficiency (AI), including Congenital Adrenal Hyperplasia (CAH)
10 5月 2021 by admin in UncategorizedComments Design Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results
10 5月 2021 by admin in UncategorizedComments Crescendo Biologics further strengthens leadership team with appointment of Dr Michael Booth as Chief Financial Officer
06 5月 2021 by admin in UncategorizedComments Syros Reports First Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
19 4月 2021 by admin in UncategorizedComments Crescendo Biologics and IAG partner to support the clinical development of CB307 with advanced imaging analysis technology
19 4月 2021 by admin in UncategorizedComments Citrine Medicine and Sinopharm Group Announce Strategic Partnership to Broaden and Accelerate Access to Rare Disease Drugs in China
16 4月 2021 by admin in UncategorizedComments New data demonstrate that Humabodies® are highly effective in generating monospecific and bispecific CAR-T cells to target solid tumours
13 4月 2021 by admin in UncategorizedComments Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies
13 4月 2021 by admin in UncategorizedComments Adicet Bio Appoints Dr. Blake Aftab as Vice President of Research
10 4月 2021 by admin in UncategorizedComments NextCure Presents Preclinical Data for NC762 at American Association for Cancer Research (AACR)
06 4月 2021 by admin in UncategorizedComments Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma
30 3月 2021 by admin in UncategorizedComments Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters
26 3月 2021 by admin in UncategorizedComments Design Therapeutics Announces Pricing of Initial Public Offering
